{"entity":{"type":"insider","cik":"0001690920","url":"/insider/0001690920","json_url":"/insider/0001690920.json","name":"Crockett Thomas Andrew","name_source":"as-filed","also_issuer":false,"cross_url":null},"coverage_statement":{"n_transactions":44,"n_filings":28,"first":"2019-01-16","last":"2024-02-21","span_basis":"filed_date"},"name_variants":[{"name":"Crockett Thomas Andrew","source":"filing","n_filings":28,"first_seen":"2019-01-16","last_seen":"2024-02-21"}],"transactions":[{"id":2995508,"accession":"0001415889-24-004710","txn_seq":2,"anchor":"line-2","filing_url":"/filing/0001415889-24-004710","line_url":"/filing/0001415889-24-004710#line-2","is_derivative":false,"issuer_cik":"0001348911","issuer_name":"KalVista Pharmaceuticals, Inc.","issuer_ticker":"KALV","issuer_name_source":null,"issuer_url":"/issuer/0001348911","owner_cik":"0001690920","owner_name":"Crockett Thomas Andrew","owner_display_name":"Crockett Thomas Andrew","owner_url":"/insider/0001690920","role":"Director, Officer (CEO)","role_mark":"D","role_mark_label":"Director","role_mark_generic":"Director","n_reporting_owners":null,"other_reporting_owners":null,"officer_title":"CEO","security_title":"Common Stock","transaction_code":"S","transaction_label":"Open-market sale","open_market":true,"acquired_disposed":"D","direction_word":"disposed","shares":24888.0,"shares_display":"24,888","price_per_share":14.1148,"price_display":"14.11","price_state":"stated","total_value":351289.1424,"total_display":"351,289.14","total_whole":"351,289","shares_owned_after":211203.0,"shares_owned_after_display":"211,203","ownership_form":"D","is_10b5_1":null,"transaction_date":"2024-02-20","filed_date":"2024-02-21","scope":"insider"},{"id":2804985,"accession":"0001415889-24-004120","txn_seq":1,"anchor":"line-1","filing_url":"/filing/0001415889-24-004120","line_url":"/filing/0001415889-24-004120#line-1","is_derivative":false,"issuer_cik":"0001348911","issuer_name":"KalVista Pharmaceuticals, Inc.","issuer_ticker":"KALV","issuer_name_source":null,"issuer_url":"/issuer/0001348911","owner_cik":"0001690920","owner_name":"Crockett Thomas Andrew","owner_display_name":"Crockett Thomas Andrew","owner_url":"/insider/0001690920","role":"Director, Officer (CEO)","role_mark":"D","role_mark_label":"Director","role_mark_generic":"Director","n_reporting_owners":null,"other_reporting_owners":null,"officer_title":"CEO","security_title":"Common Stock","transaction_code":"S","transaction_label":"Open-market sale","open_market":true,"acquired_disposed":"D","direction_word":"disposed","shares":58356.0,"shares_display":"58,356","price_per_share":15.0093,"price_display":"15.01","price_state":"stated","total_value":875882.7108,"total_display":"875,882.71","total_whole":"875,883","shares_owned_after":181676.0,"shares_owned_after_display":"181,676","ownership_form":"D","is_10b5_1":null,"transaction_date":"2024-02-14","filed_date":"2024-02-16","scope":"insider"},{"id":2483722,"accession":"0001415889-24-002625","txn_seq":2,"anchor":"line-2","filing_url":"/filing/0001415889-24-002625","line_url":"/filing/0001415889-24-002625","is_derivative":false,"issuer_cik":"0001348911","issuer_name":"KalVista Pharmaceuticals, Inc.","issuer_ticker":"KALV","issuer_name_source":null,"issuer_url":"/issuer/0001348911","owner_cik":"0001690920","owner_name":"Crockett Thomas Andrew","owner_display_name":"Crockett Thomas Andrew","owner_url":"/insider/0001690920","role":"Director, Officer (CEO)","role_mark":"D","role_mark_label":"Director","role_mark_generic":"Director","n_reporting_owners":null,"other_reporting_owners":null,"officer_title":"CEO","security_title":"Common Stock","transaction_code":"S","transaction_label":"Open-market sale","open_market":true,"acquired_disposed":"D","direction_word":"disposed","shares":10000.0,"shares_display":"10,000","price_per_share":16.219844,"price_display":"16.22","price_state":"stated","total_value":162198.44,"total_display":"162,198.44","total_whole":"162,198","shares_owned_after":118232.0,"shares_owned_after_display":"118,232","ownership_form":"D","is_10b5_1":null,"transaction_date":"2024-02-01","filed_date":"2024-02-05","scope":"insider","n_lines":2},{"id":8659037,"accession":"0001209191-23-059907","txn_seq":1,"anchor":"line-1","filing_url":"/filing/0001209191-23-059907","line_url":"/filing/0001209191-23-059907#line-1","is_derivative":false,"issuer_cik":"0001348911","issuer_name":"KalVista Pharmaceuticals, Inc.","issuer_ticker":"KALV","issuer_name_source":null,"issuer_url":"/issuer/0001348911","owner_cik":"0001690920","owner_name":"Crockett Thomas Andrew","owner_display_name":"Crockett Thomas Andrew","owner_url":"/insider/0001690920","role":"Director, Officer (CEO)","role_mark":"D","role_mark_label":"Director","role_mark_generic":"Director","n_reporting_owners":null,"other_reporting_owners":null,"officer_title":"CEO","security_title":"Common Stock","transaction_code":"S","transaction_label":"Open-market sale","open_market":true,"acquired_disposed":"D","direction_word":"disposed","shares":30000.0,"shares_display":"30,000","price_per_share":12.0151,"price_display":"12.02","price_state":"stated","total_value":360453.0,"total_display":"360,453.00","total_whole":"360,453","shares_owned_after":127532.0,"shares_owned_after_display":"127,532","ownership_form":"D","is_10b5_1":null,"transaction_date":"2023-12-27","filed_date":"2023-12-28","scope":"insider"},{"id":8255590,"accession":"0001209191-23-056267","txn_seq":2,"anchor":"line-2","filing_url":"/filing/0001209191-23-056267","line_url":"/filing/0001209191-23-056267#line-2","is_derivative":false,"issuer_cik":"0001348911","issuer_name":"KalVista Pharmaceuticals, Inc.","issuer_ticker":"KALV","issuer_name_source":null,"issuer_url":"/issuer/0001348911","owner_cik":"0001690920","owner_name":"Crockett Thomas Andrew","owner_display_name":"Crockett Thomas Andrew","owner_url":"/insider/0001690920","role":"Director, Officer (CEO)","role_mark":"D","role_mark_label":"Director","role_mark_generic":"Director","n_reporting_owners":null,"other_reporting_owners":null,"officer_title":"CEO","security_title":"Common Stock","transaction_code":"S","transaction_label":"Open-market sale","open_market":true,"acquired_disposed":"D","direction_word":"disposed","shares":14807.0,"shares_display":"14,807","price_per_share":8.2293,"price_display":"8.23","price_state":"stated","total_value":121851.2451,"total_display":"121,851.25","total_whole":"121,851","shares_owned_after":157532.0,"shares_owned_after_display":"157,532","ownership_form":"D","is_10b5_1":null,"transaction_date":"2023-11-20","filed_date":"2023-11-21","scope":"insider"},{"id":7954590,"accession":"0001209191-23-046820","txn_seq":2,"anchor":"line-2","filing_url":"/filing/0001209191-23-046820","line_url":"/filing/0001209191-23-046820#line-2","is_derivative":false,"issuer_cik":"0001348911","issuer_name":"KalVista Pharmaceuticals, Inc.","issuer_ticker":"KALV","issuer_name_source":null,"issuer_url":"/issuer/0001348911","owner_cik":"0001690920","owner_name":"Crockett Thomas Andrew","owner_display_name":"Crockett Thomas Andrew","owner_url":"/insider/0001690920","role":"Director, Officer (CEO)","role_mark":"D","role_mark_label":"Director","role_mark_generic":"Director","n_reporting_owners":null,"other_reporting_owners":null,"officer_title":"CEO","security_title":"Common Stock","transaction_code":"S","transaction_label":"Open-market sale","open_market":true,"acquired_disposed":"D","direction_word":"disposed","shares":14876.0,"shares_display":"14,876","price_per_share":10.7288,"price_display":"10.73","price_state":"stated","total_value":159601.6288,"total_display":"159,601.63","total_whole":"159,602","shares_owned_after":146756.0,"shares_owned_after_display":"146,756","ownership_form":"D","is_10b5_1":null,"transaction_date":"2023-08-18","filed_date":"2023-08-21","scope":"insider"},{"id":8112317,"accession":"0001209191-23-031292","txn_seq":2,"anchor":"line-2","filing_url":"/filing/0001209191-23-031292","line_url":"/filing/0001209191-23-031292#line-2","is_derivative":false,"issuer_cik":"0001348911","issuer_name":"KalVista Pharmaceuticals, Inc.","issuer_ticker":"KALV","issuer_name_source":null,"issuer_url":"/issuer/0001348911","owner_cik":"0001690920","owner_name":"Crockett Thomas Andrew","owner_display_name":"Crockett Thomas Andrew","owner_url":"/insider/0001690920","role":"Director, Officer (CEO)","role_mark":"D","role_mark_label":"Director","role_mark_generic":"Director","n_reporting_owners":null,"other_reporting_owners":null,"officer_title":"CEO","security_title":"Common Stock","transaction_code":"S","transaction_label":"Open-market sale","open_market":true,"acquired_disposed":"D","direction_word":"disposed","shares":5627.0,"shares_display":"5,627","price_per_share":10.1444,"price_display":"10.14","price_state":"stated","total_value":57082.5388,"total_display":"57,082.54","total_whole":"57,083","shares_owned_after":128050.0,"shares_owned_after_display":"128,050","ownership_form":"D","is_10b5_1":null,"transaction_date":"2023-05-18","filed_date":"2023-05-19","scope":"insider"},{"id":8678104,"accession":"0001209191-23-012315","txn_seq":2,"anchor":"line-2","filing_url":"/filing/0001209191-23-012315","line_url":"/filing/0001209191-23-012315#line-2","is_derivative":false,"issuer_cik":"0001348911","issuer_name":"KalVista Pharmaceuticals, Inc.","issuer_ticker":"KALV","issuer_name_source":null,"issuer_url":"/issuer/0001348911","owner_cik":"0001690920","owner_name":"Crockett Thomas Andrew","owner_display_name":"Crockett Thomas Andrew","owner_url":"/insider/0001690920","role":"Director, Officer (CEO)","role_mark":"D","role_mark_label":"Director","role_mark_generic":"Director","n_reporting_owners":null,"other_reporting_owners":null,"officer_title":"CEO","security_title":"Common Stock","transaction_code":"S","transaction_label":"Open-market sale","open_market":true,"acquired_disposed":"D","direction_word":"disposed","shares":6700.0,"shares_display":"6,700","price_per_share":7.66,"price_display":"7.66","price_state":"stated","total_value":51322.0,"total_display":"51,322.00","total_whole":"51,322","shares_owned_after":120927.0,"shares_owned_after_display":"120,927","ownership_form":"D","is_10b5_1":null,"transaction_date":"2023-02-17","filed_date":"2023-02-23","scope":"insider"},{"id":6253424,"accession":"0001209191-22-058119","txn_seq":2,"anchor":"line-2","filing_url":"/filing/0001209191-22-058119","line_url":"/filing/0001209191-22-058119#line-2","is_derivative":false,"issuer_cik":"0001348911","issuer_name":"KalVista Pharmaceuticals, Inc.","issuer_ticker":"KALV","issuer_name_source":null,"issuer_url":"/issuer/0001348911","owner_cik":"0001690920","owner_name":"Crockett Thomas Andrew","owner_display_name":"Crockett Thomas Andrew","owner_url":"/insider/0001690920","role":"Director, Officer (CEO)","role_mark":"D","role_mark_label":"Director","role_mark_generic":"Director","n_reporting_owners":null,"other_reporting_owners":null,"officer_title":"CEO","security_title":"Common Stock","transaction_code":"S","transaction_label":"Open-market sale","open_market":true,"acquired_disposed":"D","direction_word":"disposed","shares":1785.0,"shares_display":"1,785","price_per_share":5.44,"price_display":"5.44","price_state":"stated","total_value":9710.4,"total_display":"9,710.40","total_whole":"9,710","shares_owned_after":114878.0,"shares_owned_after_display":"114,878","ownership_form":"D","is_10b5_1":null,"transaction_date":"2022-11-18","filed_date":"2022-11-21","scope":"insider"},{"id":6457035,"accession":"0001209191-22-049030","txn_seq":2,"anchor":"line-2","filing_url":"/filing/0001209191-22-049030","line_url":"/filing/0001209191-22-049030#line-2","is_derivative":false,"issuer_cik":"0001348911","issuer_name":"KalVista Pharmaceuticals, Inc.","issuer_ticker":"KALV","issuer_name_source":null,"issuer_url":"/issuer/0001348911","owner_cik":"0001690920","owner_name":"Crockett Thomas Andrew","owner_display_name":"Crockett Thomas Andrew","owner_url":"/insider/0001690920","role":"Director, Officer (CEO)","role_mark":"D","role_mark_label":"Director","role_mark_generic":"Director","n_reporting_owners":null,"other_reporting_owners":null,"officer_title":"CEO","security_title":"Common Stock","transaction_code":"S","transaction_label":"Open-market sale","open_market":true,"acquired_disposed":"D","direction_word":"disposed","shares":1320.0,"shares_display":"1,320","price_per_share":17.0134,"price_display":"17.01","price_state":"stated","total_value":22457.688,"total_display":"22,457.69","total_whole":"22,458","shares_owned_after":110858.0,"shares_owned_after_display":"110,858","ownership_form":"D","is_10b5_1":null,"transaction_date":"2022-09-02","filed_date":"2022-09-07","scope":"insider"},{"id":6106400,"accession":"0001209191-22-046855","txn_seq":2,"anchor":"line-2","filing_url":"/filing/0001209191-22-046855","line_url":"/filing/0001209191-22-046855#line-2","is_derivative":false,"issuer_cik":"0001348911","issuer_name":"KalVista Pharmaceuticals, Inc.","issuer_ticker":"KALV","issuer_name_source":null,"issuer_url":"/issuer/0001348911","owner_cik":"0001690920","owner_name":"Crockett Thomas Andrew","owner_display_name":"Crockett Thomas Andrew","owner_url":"/insider/0001690920","role":"Director, Officer (CEO)","role_mark":"D","role_mark_label":"Director","role_mark_generic":"Director","n_reporting_owners":null,"other_reporting_owners":null,"officer_title":"CEO","security_title":"Common Stock","transaction_code":"S","transaction_label":"Open-market sale","open_market":true,"acquired_disposed":"D","direction_word":"disposed","shares":1797.0,"shares_display":"1,797","price_per_share":14.9641,"price_display":"14.96","price_state":"stated","total_value":26890.4877,"total_display":"26,890.49","total_whole":"26,890","shares_owned_after":112178.0,"shares_owned_after_display":"112,178","ownership_form":"D","is_10b5_1":null,"transaction_date":"2022-08-17","filed_date":"2022-08-19","scope":"insider"},{"id":6607617,"accession":"0001209191-22-018184","txn_seq":1,"anchor":"line-1","filing_url":"/filing/0001209191-22-018184","line_url":"/filing/0001209191-22-018184#line-1","is_derivative":false,"issuer_cik":"0001348911","issuer_name":"KalVista Pharmaceuticals, Inc.","issuer_ticker":"KALV","issuer_name_source":null,"issuer_url":"/issuer/0001348911","owner_cik":"0001690920","owner_name":"Crockett Thomas Andrew","owner_display_name":"Crockett Thomas Andrew","owner_url":"/insider/0001690920","role":"Director, Officer (CEO)","role_mark":"D","role_mark_label":"Director","role_mark_generic":"Director","n_reporting_owners":null,"other_reporting_owners":null,"officer_title":"CEO","security_title":"Common Stock","transaction_code":"S","transaction_label":"Open-market sale","open_market":true,"acquired_disposed":"D","direction_word":"disposed","shares":10000.0,"shares_display":"10,000","price_per_share":17.0693,"price_display":"17.07","price_state":"stated","total_value":170693.0,"total_display":"170,693.00","total_whole":"170,693","shares_owned_after":114670.0,"shares_owned_after_display":"114,670","ownership_form":"D","is_10b5_1":null,"transaction_date":"2022-03-09","filed_date":"2022-03-11","scope":"insider"},{"id":5113050,"accession":"0001209191-21-059042","txn_seq":1,"anchor":"line-1","filing_url":"/filing/0001209191-21-059042","line_url":"/filing/0001209191-21-059042#line-1","is_derivative":false,"issuer_cik":"0001348911","issuer_name":"KalVista Pharmaceuticals, Inc.","issuer_ticker":"KALV","issuer_name_source":null,"issuer_url":"/issuer/0001348911","owner_cik":"0001690920","owner_name":"Crockett Thomas Andrew","owner_display_name":"Crockett Thomas Andrew","owner_url":"/insider/0001690920","role":"Director, Officer (CEO)","role_mark":"D","role_mark_label":"Director","role_mark_generic":"Director","n_reporting_owners":null,"other_reporting_owners":null,"officer_title":"CEO","security_title":"Common Stock","transaction_code":"S","transaction_label":"Open-market sale","open_market":true,"acquired_disposed":"D","direction_word":"disposed","shares":10000.0,"shares_display":"10,000","price_per_share":17.1841,"price_display":"17.18","price_state":"stated","total_value":171841.0,"total_display":"171,841.00","total_whole":"171,841","shares_owned_after":124670.0,"shares_owned_after_display":"124,670","ownership_form":"D","is_10b5_1":null,"transaction_date":"2021-10-01","filed_date":"2021-10-04","scope":"insider"},{"id":4838264,"accession":"0001209191-21-045093","txn_seq":2,"anchor":"line-2","filing_url":"/filing/0001209191-21-045093","line_url":"/filing/0001209191-21-045093","is_derivative":false,"issuer_cik":"0001348911","issuer_name":"KalVista Pharmaceuticals, Inc.","issuer_ticker":"KALV","issuer_name_source":null,"issuer_url":"/issuer/0001348911","owner_cik":"0001690920","owner_name":"Crockett Thomas Andrew","owner_display_name":"Crockett Thomas Andrew","owner_url":"/insider/0001690920","role":"Director, Officer (CEO)","role_mark":"D","role_mark_label":"Director","role_mark_generic":"Director","n_reporting_owners":null,"other_reporting_owners":null,"officer_title":"CEO","security_title":"Common Stock","transaction_code":"S","transaction_label":"Open-market sale","open_market":true,"acquired_disposed":"D","direction_word":"disposed","shares":10000.0,"shares_display":"10,000","price_per_share":24.1476965,"price_display":"24.15","price_state":"stated","total_value":241476.965,"total_display":"241,476.96","total_whole":"241,477","shares_owned_after":134670.0,"shares_owned_after_display":"134,670","ownership_form":"D","is_10b5_1":null,"transaction_date":"2021-07-01","filed_date":"2021-07-02","scope":"insider","n_lines":2},{"id":4668713,"accession":"0001209191-21-042450","txn_seq":1,"anchor":"line-1","filing_url":"/filing/0001209191-21-042450","line_url":"/filing/0001209191-21-042450#line-1","is_derivative":false,"issuer_cik":"0001348911","issuer_name":"KalVista Pharmaceuticals, Inc.","issuer_ticker":"KALV","issuer_name_source":null,"issuer_url":"/issuer/0001348911","owner_cik":"0001690920","owner_name":"Crockett Thomas Andrew","owner_display_name":"Crockett Thomas Andrew","owner_url":"/insider/0001690920","role":"Director, Officer (CEO)","role_mark":"D","role_mark_label":"Director","role_mark_generic":"Director","n_reporting_owners":null,"other_reporting_owners":null,"officer_title":"CEO","security_title":"Common Stock","transaction_code":"S","transaction_label":"Open-market sale","open_market":true,"acquired_disposed":"D","direction_word":"disposed","shares":1067.0,"shares_display":"1,067","price_per_share":30.038,"price_display":"30.04","price_state":"stated","total_value":32050.546,"total_display":"32,050.55","total_whole":"32,051","shares_owned_after":144670.0,"shares_owned_after_display":"144,670","ownership_form":"D","is_10b5_1":null,"transaction_date":"2021-06-17","filed_date":"2021-06-22","scope":"insider"},{"id":4730166,"accession":"0001209191-21-040040","txn_seq":1,"anchor":"line-1","filing_url":"/filing/0001209191-21-040040","line_url":"/filing/0001209191-21-040040#line-1","is_derivative":false,"issuer_cik":"0001348911","issuer_name":"KalVista Pharmaceuticals, Inc.","issuer_ticker":"KALV","issuer_name_source":null,"issuer_url":"/issuer/0001348911","owner_cik":"0001690920","owner_name":"Crockett Thomas Andrew","owner_display_name":"Crockett Thomas Andrew","owner_url":"/insider/0001690920","role":"Director, Officer (CEO)","role_mark":"D","role_mark_label":"Director","role_mark_generic":"Director","n_reporting_owners":null,"other_reporting_owners":null,"officer_title":"CEO","security_title":"Common Stock","transaction_code":"S","transaction_label":"Open-market sale","open_market":true,"acquired_disposed":"D","direction_word":"disposed","shares":8933.0,"shares_display":"8,933","price_per_share":30.0549,"price_display":"30.05","price_state":"stated","total_value":268480.4217,"total_display":"268,480.42","total_whole":"268,480","shares_owned_after":145737.0,"shares_owned_after_display":"145,737","ownership_form":"D","is_10b5_1":null,"transaction_date":"2021-06-09","filed_date":"2021-06-11","scope":"insider"},{"id":5042484,"accession":"0001209191-21-025420","txn_seq":3,"anchor":"line-3","filing_url":"/filing/0001209191-21-025420","line_url":"/filing/0001209191-21-025420","is_derivative":false,"issuer_cik":"0001348911","issuer_name":"KalVista Pharmaceuticals, Inc.","issuer_ticker":"KALV","issuer_name_source":null,"issuer_url":"/issuer/0001348911","owner_cik":"0001690920","owner_name":"Crockett Thomas Andrew","owner_display_name":"Crockett Thomas Andrew","owner_url":"/insider/0001690920","role":"Director, Officer (CEO)","role_mark":"D","role_mark_label":"Director","role_mark_generic":"Director","n_reporting_owners":null,"other_reporting_owners":null,"officer_title":"CEO","security_title":"Common Stock","transaction_code":"S","transaction_label":"Open-market sale","open_market":true,"acquired_disposed":"D","direction_word":"disposed","shares":10000.0,"shares_display":"10,000","price_per_share":27.443623,"price_display":"27.44","price_state":"stated","total_value":274436.23,"total_display":"274,436.23","total_whole":"274,436","shares_owned_after":160220.0,"shares_owned_after_display":"160,220","ownership_form":"D","is_10b5_1":null,"transaction_date":"2021-04-01","filed_date":"2021-04-05","scope":"insider","n_lines":3},{"id":5036354,"accession":"0001209191-21-014515","txn_seq":4,"anchor":"line-4","filing_url":"/filing/0001209191-21-014515","line_url":"/filing/0001209191-21-014515","is_derivative":false,"issuer_cik":"0001348911","issuer_name":"KalVista Pharmaceuticals, Inc.","issuer_ticker":"KALV","issuer_name_source":null,"issuer_url":"/issuer/0001348911","owner_cik":"0001690920","owner_name":"Crockett Thomas Andrew","owner_display_name":"Crockett Thomas Andrew","owner_url":"/insider/0001690920","role":"Director, Officer (CEO)","role_mark":"D","role_mark_label":"Director","role_mark_generic":"Director","n_reporting_owners":null,"other_reporting_owners":null,"officer_title":"CEO","security_title":"Common Stock","transaction_code":"S","transaction_label":"Open-market sale","open_market":true,"acquired_disposed":"D","direction_word":"disposed","shares":10000.0,"shares_display":"10,000","price_per_share":33.55383167,"price_display":"33.55","price_state":"stated","total_value":335538.3167,"total_display":"335,538.32","total_whole":"335,538","shares_owned_after":171702.0,"shares_owned_after_display":"171,702","ownership_form":"D","is_10b5_1":null,"transaction_date":"2021-02-23","filed_date":"2021-02-25","scope":"insider","n_lines":4},{"id":5144016,"accession":"0001209191-21-002279","txn_seq":3,"anchor":"line-3","filing_url":"/filing/0001209191-21-002279","line_url":"/filing/0001209191-21-002279","is_derivative":false,"issuer_cik":"0001348911","issuer_name":"KalVista Pharmaceuticals, Inc.","issuer_ticker":"KALV","issuer_name_source":null,"issuer_url":"/issuer/0001348911","owner_cik":"0001690920","owner_name":"Crockett Thomas Andrew","owner_display_name":"Crockett Thomas Andrew","owner_url":"/insider/0001690920","role":"Director, Officer (CEO)","role_mark":"D","role_mark_label":"Director","role_mark_generic":"Director","n_reporting_owners":null,"other_reporting_owners":null,"officer_title":"CEO","security_title":"Common Stock","transaction_code":"S","transaction_label":"Open-market sale","open_market":true,"acquired_disposed":"D","direction_word":"disposed","shares":10000.0,"shares_display":"10,000","price_per_share":18.19041382,"price_display":"18.19","price_state":"stated","total_value":181904.1382,"total_display":"181,904.14","total_whole":"181,904","shares_owned_after":186234.0,"shares_owned_after_display":"186,234","ownership_form":"D","is_10b5_1":null,"transaction_date":"2021-01-04","filed_date":"2021-01-06","scope":"insider","n_lines":2},{"id":2658602,"accession":"0001209191-20-055588","txn_seq":5,"anchor":"line-5","filing_url":"/filing/0001209191-20-055588","line_url":"/filing/0001209191-20-055588","is_derivative":false,"issuer_cik":"0001348911","issuer_name":"KalVista Pharmaceuticals, Inc.","issuer_ticker":"KALV","issuer_name_source":null,"issuer_url":"/issuer/0001348911","owner_cik":"0001690920","owner_name":"Crockett Thomas Andrew","owner_display_name":"Crockett Thomas Andrew","owner_url":"/insider/0001690920","role":"Director, Officer (CEO)","role_mark":"D","role_mark_label":"Director","role_mark_generic":"Director","n_reporting_owners":null,"other_reporting_owners":null,"officer_title":"CEO","security_title":"Common Stock","transaction_code":"S","transaction_label":"Open-market sale","open_market":true,"acquired_disposed":"D","direction_word":"disposed","shares":22545.0,"shares_display":"22,545","price_per_share":18.329865690840542,"price_display":"18.33","price_state":"stated","total_value":413246.822,"total_display":"413,246.82","total_whole":"413,247","shares_owned_after":199113.0,"shares_owned_after_display":"199,113","ownership_form":"D","is_10b5_1":null,"transaction_date":"2020-10-21","filed_date":"2020-10-22","scope":"insider","n_lines":3},{"id":2658585,"accession":"0001209191-20-055588","txn_seq":2,"anchor":"line-2","filing_url":"/filing/0001209191-20-055588","line_url":"/filing/0001209191-20-055588","is_derivative":false,"issuer_cik":"0001348911","issuer_name":"KalVista Pharmaceuticals, Inc.","issuer_ticker":"KALV","issuer_name_source":null,"issuer_url":"/issuer/0001348911","owner_cik":"0001690920","owner_name":"Crockett Thomas Andrew","owner_display_name":"Crockett Thomas Andrew","owner_url":"/insider/0001690920","role":"Director, Officer (CEO)","role_mark":"D","role_mark_label":"Director","role_mark_generic":"Director","n_reporting_owners":null,"other_reporting_owners":null,"officer_title":"CEO","security_title":"Common Stock","transaction_code":"S","transaction_label":"Open-market sale","open_market":true,"acquired_disposed":"D","direction_word":"disposed","shares":15994.0,"shares_display":"15,994","price_per_share":17.492706189821185,"price_display":"17.49","price_state":"stated","total_value":279778.3428,"total_display":"279,778.34","total_whole":"279,778","shares_owned_after":222741.0,"shares_owned_after_display":"222,741","ownership_form":"D","is_10b5_1":null,"transaction_date":"2020-10-20","filed_date":"2020-10-22","scope":"insider","n_lines":2},{"id":2145804,"accession":"0001209191-20-055362","txn_seq":2,"anchor":"line-2","filing_url":"/filing/0001209191-20-055362","line_url":"/filing/0001209191-20-055362#line-2","is_derivative":false,"issuer_cik":"0001348911","issuer_name":"KalVista Pharmaceuticals, Inc.","issuer_ticker":"KALV","issuer_name_source":null,"issuer_url":"/issuer/0001348911","owner_cik":"0001690920","owner_name":"Crockett Thomas Andrew","owner_display_name":"Crockett Thomas Andrew","owner_url":"/insider/0001690920","role":"Director, Officer (CEO)","role_mark":"D","role_mark_label":"Director","role_mark_generic":"Director","n_reporting_owners":null,"other_reporting_owners":null,"officer_title":"CEO","security_title":"Common Stock","transaction_code":"S","transaction_label":"Open-market sale","open_market":true,"acquired_disposed":"D","direction_word":"disposed","shares":1261.0,"shares_display":"1,261","price_per_share":17.0056,"price_display":"17.01","price_state":"stated","total_value":21444.0616,"total_display":"21,444.06","total_whole":"21,444","shares_owned_after":236959.0,"shares_owned_after_display":"236,959","ownership_form":"D","is_10b5_1":null,"transaction_date":"2020-10-16","filed_date":"2020-10-20","scope":"insider"},{"id":3150497,"accession":"0001567619-20-002452","txn_seq":1,"anchor":"line-1","filing_url":"/filing/0001567619-20-002452","line_url":"/filing/0001567619-20-002452#line-1","is_derivative":false,"issuer_cik":"0001348911","issuer_name":"KalVista Pharmaceuticals, Inc.","issuer_ticker":"KALV","issuer_name_source":null,"issuer_url":"/issuer/0001348911","owner_cik":"0001690920","owner_name":"Crockett Thomas Andrew","owner_display_name":"Crockett Thomas Andrew","owner_url":"/insider/0001690920","role":"Director, Officer (CEO)","role_mark":"D","role_mark_label":"Director","role_mark_generic":"Director","n_reporting_owners":null,"other_reporting_owners":null,"officer_title":"CEO","security_title":"Common Stock","transaction_code":"S","transaction_label":"Open-market sale","open_market":true,"acquired_disposed":"D","direction_word":"disposed","shares":200.0,"shares_display":"200","price_per_share":17.05,"price_display":"17.05","price_state":"stated","total_value":3410.0,"total_display":"3,410.00","total_whole":"3,410","shares_owned_after":238220.0,"shares_owned_after_display":"238,220","ownership_form":"D","is_10b5_1":null,"transaction_date":"2020-02-05","filed_date":"2020-02-07","scope":"insider"},{"id":8018804,"accession":"0001567619-19-023611","txn_seq":1,"anchor":"line-1","filing_url":"/filing/0001567619-19-023611","line_url":"/filing/0001567619-19-023611#line-1","is_derivative":false,"issuer_cik":"0001348911","issuer_name":"KalVista Pharmaceuticals, Inc.","issuer_ticker":"KALV","issuer_name_source":null,"issuer_url":"/issuer/0001348911","owner_cik":"0001690920","owner_name":"Crockett Thomas Andrew","owner_display_name":"Crockett Thomas Andrew","owner_url":"/insider/0001690920","role":"Director, Officer (CEO)","role_mark":"D","role_mark_label":"Director","role_mark_generic":"Director","n_reporting_owners":null,"other_reporting_owners":null,"officer_title":"CEO","security_title":"Common Stock","transaction_code":"S","transaction_label":"Open-market sale","open_market":true,"acquired_disposed":"D","direction_word":"disposed","shares":2300.0,"shares_display":"2,300","price_per_share":17.0219,"price_display":"17.02","price_state":"stated","total_value":39150.37,"total_display":"39,150.37","total_whole":"39,150","shares_owned_after":238420.0,"shares_owned_after_display":"238,420","ownership_form":"D","is_10b5_1":null,"transaction_date":"2019-12-20","filed_date":"2019-12-26","scope":"insider"},{"id":8139918,"accession":"0001567619-19-023162","txn_seq":3,"anchor":"line-3","filing_url":"/filing/0001567619-19-023162","line_url":"/filing/0001567619-19-023162#line-3","is_derivative":false,"issuer_cik":"0001348911","issuer_name":"KalVista Pharmaceuticals, Inc.","issuer_ticker":"KALV","issuer_name_source":null,"issuer_url":"/issuer/0001348911","owner_cik":"0001690920","owner_name":"Crockett Thomas Andrew","owner_display_name":"Crockett Thomas Andrew","owner_url":"/insider/0001690920","role":"Director, Officer (CEO)","role_mark":"D","role_mark_label":"Director","role_mark_generic":"Director","n_reporting_owners":null,"other_reporting_owners":null,"officer_title":"CEO","security_title":"Common Stock","transaction_code":"S","transaction_label":"Open-market sale","open_market":true,"acquired_disposed":"D","direction_word":"disposed","shares":5400.0,"shares_display":"5,400","price_per_share":17.0585,"price_display":"17.06","price_state":"stated","total_value":92115.9,"total_display":"92,115.90","total_whole":"92,116","shares_owned_after":240720.0,"shares_owned_after_display":"240,720","ownership_form":"D","is_10b5_1":null,"transaction_date":"2019-12-16","filed_date":"2019-12-16","scope":"insider"},{"id":8139914,"accession":"0001567619-19-023162","txn_seq":2,"anchor":"line-2","filing_url":"/filing/0001567619-19-023162","line_url":"/filing/0001567619-19-023162#line-2","is_derivative":false,"issuer_cik":"0001348911","issuer_name":"KalVista Pharmaceuticals, Inc.","issuer_ticker":"KALV","issuer_name_source":null,"issuer_url":"/issuer/0001348911","owner_cik":"0001690920","owner_name":"Crockett Thomas Andrew","owner_display_name":"Crockett Thomas Andrew","owner_url":"/insider/0001690920","role":"Director, Officer (CEO)","role_mark":"D","role_mark_label":"Director","role_mark_generic":"Director","n_reporting_owners":null,"other_reporting_owners":null,"officer_title":"CEO","security_title":"Common Stock","transaction_code":"S","transaction_label":"Open-market sale","open_market":true,"acquired_disposed":"D","direction_word":"disposed","shares":2200.0,"shares_display":"2,200","price_per_share":17.062,"price_display":"17.06","price_state":"stated","total_value":37536.4,"total_display":"37,536.40","total_whole":"37,536","shares_owned_after":246120.0,"shares_owned_after_display":"246,120","ownership_form":"D","is_10b5_1":null,"transaction_date":"2019-12-13","filed_date":"2019-12-16","scope":"insider"},{"id":8139910,"accession":"0001567619-19-023162","txn_seq":1,"anchor":"line-1","filing_url":"/filing/0001567619-19-023162","line_url":"/filing/0001567619-19-023162#line-1","is_derivative":false,"issuer_cik":"0001348911","issuer_name":"KalVista Pharmaceuticals, Inc.","issuer_ticker":"KALV","issuer_name_source":null,"issuer_url":"/issuer/0001348911","owner_cik":"0001690920","owner_name":"Crockett Thomas Andrew","owner_display_name":"Crockett Thomas Andrew","owner_url":"/insider/0001690920","role":"Director, Officer (CEO)","role_mark":"D","role_mark_label":"Director","role_mark_generic":"Director","n_reporting_owners":null,"other_reporting_owners":null,"officer_title":"CEO","security_title":"Common Stock","transaction_code":"S","transaction_label":"Open-market sale","open_market":true,"acquired_disposed":"D","direction_word":"disposed","shares":100.0,"shares_display":"100","price_per_share":17.0,"price_display":"17.00","price_state":"stated","total_value":1700.0,"total_display":"1,700.00","total_whole":"1,700","shares_owned_after":248320.0,"shares_owned_after_display":"248,320","ownership_form":"D","is_10b5_1":null,"transaction_date":"2019-12-12","filed_date":"2019-12-16","scope":"insider"},{"id":8558676,"accession":"0001567619-19-014946","txn_seq":1,"anchor":"line-1","filing_url":"/filing/0001567619-19-014946","line_url":"/filing/0001567619-19-014946#line-1","is_derivative":false,"issuer_cik":"0001348911","issuer_name":"KalVista Pharmaceuticals, Inc.","issuer_ticker":"KALV","issuer_name_source":null,"issuer_url":"/issuer/0001348911","owner_cik":"0001690920","owner_name":"Crockett Thomas Andrew","owner_display_name":"Crockett Thomas Andrew","owner_url":"/insider/0001690920","role":"Director, Officer (CEO)","role_mark":"D","role_mark_label":"Director","role_mark_generic":"Director","n_reporting_owners":null,"other_reporting_owners":null,"officer_title":"CEO","security_title":"Common Stock","transaction_code":"S","transaction_label":"Open-market sale","open_market":true,"acquired_disposed":"D","direction_word":"disposed","shares":10000.0,"shares_display":"10,000","price_per_share":17.0407,"price_display":"17.04","price_state":"stated","total_value":170407.0,"total_display":"170,407.00","total_whole":"170,407","shares_owned_after":248510.0,"shares_owned_after_display":"248,510","ownership_form":"D","is_10b5_1":null,"transaction_date":"2019-07-15","filed_date":"2019-07-17","scope":"insider"},{"id":7868493,"accession":"0001567619-19-009060","txn_seq":2,"anchor":"line-2","filing_url":"/filing/0001567619-19-009060","line_url":"/filing/0001567619-19-009060","is_derivative":false,"issuer_cik":"0001348911","issuer_name":"KalVista Pharmaceuticals, Inc.","issuer_ticker":"KALV","issuer_name_source":null,"issuer_url":"/issuer/0001348911","owner_cik":"0001690920","owner_name":"Crockett Thomas Andrew","owner_display_name":"Crockett Thomas Andrew","owner_url":"/insider/0001690920","role":"Director, Officer (CEO)","role_mark":"D","role_mark_label":"Director","role_mark_generic":"Director","n_reporting_owners":null,"other_reporting_owners":null,"officer_title":"CEO","security_title":"Common Stock","transaction_code":"S","transaction_label":"Open-market sale","open_market":true,"acquired_disposed":"D","direction_word":"disposed","shares":10000.0,"shares_display":"10,000","price_per_share":24.795772,"price_display":"24.80","price_state":"stated","total_value":247957.72,"total_display":"247,957.72","total_whole":"247,958","shares_owned_after":258810.0,"shares_owned_after_display":"258,810","ownership_form":"D","is_10b5_1":null,"transaction_date":"2019-04-15","filed_date":"2019-04-23","scope":"insider","n_lines":2},{"id":7963788,"accession":"0001567619-19-007013","txn_seq":1,"anchor":"line-1","filing_url":"/filing/0001567619-19-007013","line_url":"/filing/0001567619-19-007013#line-1","is_derivative":false,"issuer_cik":"0001348911","issuer_name":"KalVista Pharmaceuticals, Inc.","issuer_ticker":"KALV","issuer_name_source":null,"issuer_url":"/issuer/0001348911","owner_cik":"0001690920","owner_name":"Crockett Thomas Andrew","owner_display_name":"Crockett Thomas Andrew","owner_url":"/insider/0001690920","role":"Director, Officer (CEO)","role_mark":"D","role_mark_label":"Director","role_mark_generic":"Director","n_reporting_owners":null,"other_reporting_owners":null,"officer_title":"CEO","security_title":"Common Stock","transaction_code":"S","transaction_label":"Open-market sale","open_market":true,"acquired_disposed":"D","direction_word":"disposed","shares":3000.0,"shares_display":"3,000","price_per_share":30.1613,"price_display":"30.16","price_state":"stated","total_value":90483.9,"total_display":"90,483.90","total_whole":"90,484","shares_owned_after":268510.0,"shares_owned_after_display":"268,510","ownership_form":"D","is_10b5_1":null,"transaction_date":"2019-03-14","filed_date":"2019-03-15","scope":"insider"},{"id":8042303,"accession":"0001567619-19-001252","txn_seq":2,"anchor":"line-2","filing_url":"/filing/0001567619-19-001252","line_url":"/filing/0001567619-19-001252","is_derivative":false,"issuer_cik":"0001348911","issuer_name":"KalVista Pharmaceuticals, Inc.","issuer_ticker":"KALV","issuer_name_source":null,"issuer_url":"/issuer/0001348911","owner_cik":"0001690920","owner_name":"Crockett Thomas Andrew","owner_display_name":"Crockett Thomas Andrew","owner_url":"/insider/0001690920","role":"Director, Officer (CEO)","role_mark":"D","role_mark_label":"Director","role_mark_generic":"Director","n_reporting_owners":null,"other_reporting_owners":null,"officer_title":"CEO","security_title":"Common Stock","transaction_code":"S","transaction_label":"Open-market sale","open_market":true,"acquired_disposed":"D","direction_word":"disposed","shares":10000.0,"shares_display":"10,000","price_per_share":19.33282919,"price_display":"19.33","price_state":"stated","total_value":193328.2919,"total_display":"193,328.29","total_whole":"193,328","shares_owned_after":272411.0,"shares_owned_after_display":"272,411","ownership_form":"D","is_10b5_1":null,"transaction_date":"2019-01-14","filed_date":"2019-01-16","scope":"insider","n_lines":2}],"collapsed":true,"next_cursor":null,"ledger_fault":false,"count":{"value":44,"kind":"exact"},"open_market_only":false,"composition":{"kind":"exact","rows":[{"code":"P","label":"Open-market purchase","n":0,"open_market":true},{"code":"S","label":"Open-market sale","n":44,"open_market":true},{"code":"M","label":"Option exercise","n":0,"open_market":false},{"code":"A","label":"Grant or award","n":0,"open_market":false},{"code":"F","label":"Tax withholding","n":0,"open_market":false},{"code":"D","label":"Disposition to the issuer","n":0,"open_market":false},{"code":"X","label":"In-the-money option exercise","n":0,"open_market":false}],"total":44},"affiliations":[{"type":"issuer","type_label":"ISSUER","cik":"0001348911","name":"KalVista Pharmaceuticals, Inc.","url":"/issuer/0001348911","role":"Director, Officer (CEO)","n_filings":28,"first_seen":"2019-01-16","last_seen":"2024-02-21"}],"order_statement":"Newest transaction date first, id breaking the tie.","canonical_url":"https://ebomi.com/insider/0001690920","retrieved_at":"2026-08-22T14:48:48+00:00","coverage":{"filings":1506293,"transactions":4290787,"issuers":28597,"insiders":152303,"first_filed_date":"2003-06-30","last_filed_date":"2026-08-21","last_ingest":"2026-08-22T05:23:40.159918+00:00","counts_are":{"filings":"estimate","transactions":"estimate","issuers":"estimate","insiders":"estimate"},"source":"SEC EDGAR Form 4 filings, parsed by ebomi","fault":false},"license":{"underlying_records":"US SEC filings are public records of the United States government and are not subject to copyright. The transactional facts in them are not ours to license.","this_presentation":"The parsing, normalisation, curation, and presentation are ebomi's own work.","grant":"undecided","grant_note":"The open licence for ebomi's own layer is an open owner decision (SPEC-20260731T1159Z open question 3: CC BY 4.0 or CC0 with a citation request). Until it is taken, no grant is asserted here.","citation_request":"Balogh, A. Insider trading. Scientific Data 10, 237 (2023)","url":"https://ebomi.com/license"},"fair_use":{"policy":"These JSON endpoints are open and unauthenticated. Please read them at a human pace, identify your client in the User-Agent header, and use the published dataset for bulk work rather than crawling page by page.","bulk_alternative":"doi:10.1038/s41597-023-02147-6"}}